Latest Developments in the Treatment of Pulmonary Arterial Hypertension

Latest Developments in the Treatment of Pulmonary Arterial Hypertension 

 

Guest: Robert P. Frantz, M.D.

Host: Kyle Klarich, M.D.

 

Pulmonary arterial hypertension (PAH) is a serious disease manifested by vasoconstriction and obliteration of the pulmonary arterial vasculature resulting in rise in pulmonary artery pressure and resistance and culminating in right heart failure. Listeners will learn more about traditional treatments for PAH, as well as new anti-proliferative therapies in active clinical investigation, and what that means for the future of treatment.

 

Topics Discussed:

• What is most new and exciting in the treatment of pulmonary arterial hypertension?
• What monitoring is necessary in order to safely use sotatercept?
• What future developments do you envision for the field of pulmonary hypertension?

 

Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices.

LinkedIn: Mayo Clinic Cardiovascular Services

Cardiovascular Education App:
The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today!

No CME credit offered for this episode.

Podcast episode transcript found here.